Scientometrics
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 7, 2023; 29(37): 5339-5360
Published online Oct 7, 2023. doi: 10.3748/wjg.v29.i37.5339
Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023)
Jin-Jin Dai, Ya-Fei Zhang, Zhen-Hua Zhang
Jin-Jin Dai, Department of Infectious Diseases, Suzhou Hospital of Anhui Medical University, Suzhou 234000, Anhui Province, China
Jin-Jin Dai, Ya-Fei Zhang, Zhen-Hua Zhang, Department of Infectious Diseases, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China
Author contributions: Zhang ZH and Dai JJ conceived and designed the study; Dai JJ performed the research, analyzed the data and wrote the manuscript; Zhang ZH and Zhang YF supervised the study; All authors have read and approved the final manuscript as submitted.
Supported by National Science Foundation of China, No. 81273142; Anhui Provincial Natural Science Foundation, No. 2108085MH298; University Scientific Research Project of Anhui Provincial Education Department, No. KJ2021A0323; Fund of Anhui Medical University, No. 2021xkj196; Clinical Medicine project of Anhui Medical University, No. 2021LCXK027; The Second Hospital of Anhui Medical University Natural Science Foundation, No. 2019GMFY02.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhen-Hua Zhang, MD, Professor, Department of Infectious Diseases, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, Anhui Province, China. zzh1974cn@163.com
Received: June 25, 2023
Peer-review started: June 25, 2023
First decision: July 23, 2023
Revised: July 26, 2023
Accepted: September 4, 2023
Article in press: September 4, 2023
Published online: October 7, 2023
Processing time: 92 Days and 6.3 Hours
Core Tip

Core Tip: A total of 10829 articles published between 2010-2023 were identified through a bibliometric analysis to explore the trends and hotspots of treatment for nonalcoholic fatty liver disease (NAFLD). Replacing NAFLD/nonalcoholic steatohepatitis with metabolic dysfunction-associated fatty liver disease has been shown to greatly promote transformation of the treatment strategy of the disease. Research on gut microbiomes and traditional medicine will continue to be a short-term research hotspot. Obeticholic acid (phase 3 clinical validation) and semaglutide (under study) are likely to become the first approved drugs for NAFLD treatment.